Related Experiment Video
Updated: Jun 10, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Metformin: taking away the candy for cancer?
Mathilde Jalving1, Jourik A Gietema, Joop D Lefrandt
1Department of Medical Oncology, University Medical Centre Groningen, Groningen, The Netherlands. m.jalving@int.umcg.nl
European Journal of Cancer (Oxford, England : 1990)
|July 27, 2010
Summary
Metformin, an anti-diabetic drug, shows promise as an anti-cancer agent by reducing cancer risk and improving treatment response. It combats cancer by targeting insulin resistance and key cell growth pathways.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) is linked to increased cancer risk and mortality, potentially due to insulin resistance and activated growth factor signaling pathways.
- Metformin, a T2DM drug, has demonstrated a dose-dependent reduction in cancer risk in population studies.
- Metformin enhances pathological tumor response rates in breast cancer patients receiving neoadjuvant chemotherapy, suggesting anti-cancer properties.
Purpose of the Study:
- To review the role of T2DM and insulin resistance in carcinogenesis.
- To explore the preclinical rationale and mechanisms behind metformin's anti-cancer effects.
- To discuss the current and future clinical applications of metformin as an anti-cancer drug.
Main Methods:
- Literature review of studies on metformin, T2DM, insulin resistance, and cancer.
- Analysis of preclinical data on metformin's molecular mechanisms of action.
- Examination of clinical trial data regarding metformin's efficacy in cancer treatment.
Main Results:
- Metformin activates AMP-activated protein kinase (AMPK), inhibiting mTOR signaling, protein synthesis, and gluconeogenesis.
- AMPK activation by metformin leads to cell cycle arrest, apoptosis, and reduced growth factor signaling.
- Metformin's ability to reverse insulin resistance presents an attractive strategy for cancer prevention and treatment.
Conclusions:
- Metformin's multifaceted mechanisms, including AMPK activation and mTOR inhibition, offer a strong preclinical basis for its anti-cancer potential.
- Metformin represents a promising, repurposed drug for novel anti-cancer therapies, particularly in patients with or without T2DM.
- Further clinical investigation is warranted to fully establish metformin's role in oncology.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...